Hélène Peyro-Saint-Paul
Directeur Technique/Scientifique/R&D chez QIAGEN MARSEILLE
Postes actifs de Hélène Peyro-Saint-Paul
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| QIAGEN MARSEILLE | Directeur Technique/Scientifique/R&D | 26/01/2009 | - |
Historique de carrière de Hélène Peyro-Saint-Paul
Anciens postes connus de Hélène Peyro-Saint-Paul
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Hélène Peyro-Saint-Paul
| Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
| ESSEC Business School | Masters Business Admin |
Statistiques
Internationale
| France | 6 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 4 |
| Commercial Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
| Université Pierre et Marie Curie | Consumer Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
- Bourse
- Insiders
- Hélène Peyro-Saint-Paul
- Expérience